Figure 2.
Characterization of the IFNα-treated MPN patient cohort. (A) Distribution of MPN diseases. (B) Distribution of MPN driver mutations. (C) Diseases and the molecular profile determined using an NGS myeloid panel of 77 genes of the first sample collected from the 48 patients in the studied cohort. P45 presented 2 diseases, ET/PV, based on its molecular profile (JAK2V617F and CALRm) and its high platelets count and hematocrit (75%) (D) Percent of hematologic response, nonresponse, or intolerance among patients with JAK2V617F or CALRm MPNs.

Characterization of the IFNα-treated MPN patient cohort. (A) Distribution of MPN diseases. (B) Distribution of MPN driver mutations. (C) Diseases and the molecular profile determined using an NGS myeloid panel of 77 genes of the first sample collected from the 48 patients in the studied cohort. P45 presented 2 diseases, ET/PV, based on its molecular profile (JAK2V617F and CALRm) and its high platelets count and hematocrit (75%) (D) Percent of hematologic response, nonresponse, or intolerance among patients with JAK2V617F or CALRm MPNs.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal